Related Experiment Video
Updated: Oct 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Immunotherapies in acute leukemia
Nicolas Boissel1, Florence Rabian1
1Hematology Adolescent and Young Adult Unit, Saint-Louis Hospital, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France; URP-3518, Institut de Recherche Saint-Louis, Université de Paris, 75010 Paris, France.
Immunotherapy, including antibody-drug conjugates and CAR T-cells, shows significant progress in treating acute leukemias (AML and ALL). New strategies like checkpoint inhibitors are improving survival rates for acute myeloid leukemia patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Immunotherapy has become a leading therapeutic strategy for acute leukemias over the last decade.
- Antibody-drug conjugates are integrated into chemotherapy regimens for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Purpose of the Study:
- To review antibody-derived therapeutic strategies in acute leukemias.
- To highlight recently approved drugs and emerging immunotherapies for AML and ALL.
Main Methods:
- Review of recent clinical trials and approved therapies.
- Focus on antibody-based treatments including conjugates, immune cell engagers, and CAR T-cells.
- Exploration of novel immunotherapies like checkpoint inhibitors (e.g., TIM-3, CD47) in combination therapies.
Main Results:
- CD19-targeting therapies and CAR T-cells are approved for relapsed/refractory B-cell ALL.
- Emerging immunotherapies show promise in combination with hypomethylating agents for unfit AML patients.
- Established safety profiles for novel combination strategies in AML.
Conclusions:
- Antibody-derived immunotherapies represent a major advancement in acute leukemia treatment.
- Approved CD19-targeting agents offer new hope for B-cell ALL patients.
- Ongoing research into novel immunotherapies and combinations is crucial for improving outcomes in AML and ALL.
More Related Videos
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...